This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Feuerstein's Biotech-Stock Mailbag: Elan

I received a few barbed emails from folks angry that I ended this Elan column Wednesday by stating that I "felt a whole lot better" after bapineuzumab's stumble.

"MM" emailed to say he thought the comment was "disgusting."

"I have no idea how you can feel a 'whole lot better' when an Alzheimer drug fails," he added. "Millions of people suffer from this devastating disease and you're happy because a drug failed and you were right and some shorts made some money? Absolutely disgusting. Writers for Wall Street rags have no soul."

My joy this week comes from being right about the stocks I cover in this column and others. That's what I do -- I write about stocks. When those stocks behave the way I predicted they would -- up or down -- I'm happy. When they don't, no one is more angry at myself than me.

If you invest in biotech stocks, your main concern should be the performance of those stocks. You should be making investment decisions based on whatever flavor of stock-picking floats your boat -- fundamentals, charts, momentum, value, growth, etc.

What you shouldn't be doing is getting emotionally involved in your stocks. Sure, that's tougher in biotech since many of these companies are seeking cures or treatments for horrible diseases. But once you become a cheerleader for a cure, you're no longer an objective investor. In other words, you're in trouble.

Alzheimer's is a horrific disease that affects millions of people and their families. I hope that one day someone develops a drug that can treat Alzheimer's effectively. But I don't write about Alzheimer's disease or cancer or AIDS. I write about the stocks of companies that seek to develop drugs for those diseases. Those are two very different things.

4 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs